Primary Sclerosing Cholangitis (PSC)

Welcome to the online home of the Chris M. Carlos and Catherine Nicole Jockisch Carlos Endowment for Primary Sclerosing Cholangitis (PSC). Thanks to support provided by this endowment, dedicated Mayo Clinic investigators and their teams are making strides to better understand and treat PSC patients, with the ultimate goal of developing a cure for this disease.

Follow the PSC page and stay up-to-date as we post news about advances in PSC research, clinical trials, and available resources.

PUBLIC PAGE
Jun 3, 2019

PSC literature elsewhere: Ursodeoxycholic acid therapy in pediatric PSC

By Konstantinos N. Lazaridis, M.D. @klazaridis
Recently, we have made the decision to include periodically in our PSC blog commentaries of selected clinical studies published by other groups. This tactic aims at keeping the followers of this blog informed about current efforts of the academic community at large to better understand and treat PSC. [...]
PSC literature elsewhere: Ursodeoxycholic acid therapy in pediatric PSC
May 20, 2019

Efficacy and safety of curcumin in PSC: an open label pilot study

By Konstantinos N. Lazaridis, M.D. @klazaridis
In this month’s issue of the Scandinavian Journal of Gastroenterology John E. Eaton et al., reports on the results of a 12-week open-label pilot study to examine whether curcumin, a naturally occurring compound, could reduce the markers of cholestasis in patients with PSC. Curcumin is the principal curcuminoid of [...]
Efficacy and safety of curcumin in PSC: an open label pilot study
May 6, 2019

Cholangiocyte Pathobiology

By Konstantinos N. Lazaridis, M.D. @klazaridis
  In a review published in Nature Reviews Gastroenterology and Hepatology this month (see below), Jesus Banales et al., provides an excellent and comprehensive overview of cholangiocyte pathobiology as relates to the development of biliary diseases like PSC. Initially, the authors emphasize on the normal function of cholangiocytes, [...]
Cholangiocyte Pathobiology
Apr 22, 2019

Potential Impact of cfDNA Technologies in Disease Management

By Ethan McConkey, Moderator @ethanmcconkey
Cell free DNA (cfDNA) are degraded DNA fragments released to the blood stream during health and disease. This discovery was made more than 50 years ago. However, it was not until recently with the advent, scalability and affordability of next generation sequencing that cfDNA has become an approach to study biomarkers for disease [...]
Potential Impact of cfDNA Technologies in Disease Management
Apr 8, 2019

Validation of the PREsTo machine learning algorithm for the prediction of disease progression in patients with PSC

By Ethan McConkey, Moderator @ethanmcconkey
In an abstract presented this week at the 2019 European Association for the Study of the Liver (EASL) meeting in Vienna, Austria, Dr. John Eaton from Mayo Clinic, Rochester, MN, reported the confirmation of the PREsTo machine learning algorithm for the prognostication of disease progression in a randomized trial [...]
Validation of the PREsTo machine learning algorithm for the prediction of disease progression in patients with PSC

Invite Others

Send an email to invite people you know to join the Primary Sclerosing Cholangitis (PSC) page.

We'll include this text in the user's invitation.